Ritonavir Soft Gelatin Capsules



Indications and Reactions:

Role Indications Reactions
Primary
Hiv Infection 52.7%
Drug Use For Unknown Indication 27.0%
Drug Exposure During Pregnancy 5.5%
Antiretroviral Therapy 1.5%
Prophylaxis 1.3%
Hypertension 1.2%
Diabetes Mellitus 1.1%
Antibiotic Prophylaxis 1.1%
Antifungal Prophylaxis 1.0%
Product Used For Unknown Indication 0.9%
Systemic Antiviral Treatment 0.9%
Hiv Test Positive 0.9%
Medical Diet 0.7%
Diarrhoea 0.7%
Acquired Immunodeficiency Syndrome 0.7%
Depression 0.6%
Myocardial Infarction 0.6%
Neuropathy Peripheral 0.6%
Anaemia 0.6%
Antiviral Prophylaxis 0.5%
Death 32.2%
Vomiting 7.6%
Premature Baby 6.7%
Abortion Spontaneous 5.2%
Sepsis 5.2%
Weight Decreased 4.8%
Myocardial Infarction 4.3%
Drug Exposure During Pregnancy 3.7%
Pyrexia 3.5%
Osteonecrosis 3.0%
Haemorrhage Intracranial 2.8%
Renal Failure 2.8%
Pneumonia 2.6%
Cerebral Haemorrhage 2.4%
Thrombocytopenia 2.4%
Abortion Induced 2.2%
Hiv Infection 2.2%
Respiratory Failure 2.2%
Upper Gastrointestinal Haemorrhage 2.2%
Immune Reconstitution Syndrome 2.0%
Secondary
Hiv Infection 39.7%
Drug Use For Unknown Indication 32.0%
Diabetes Mellitus 5.3%
Myocardial Infarction 3.2%
Antifungal Prophylaxis 2.0%
Drug Exposure During Pregnancy 2.0%
Gastrooesophageal Reflux Disease 1.7%
Antiretroviral Therapy 1.5%
Diarrhoea 1.4%
Antibiotic Prophylaxis 1.3%
Hypertension 1.2%
Medical Diet 1.2%
Hypothyroidism 1.1%
Prophylaxis 1.1%
Drug Hypersensitivity 1.0%
Headache 0.9%
Neuropathy Peripheral 0.9%
Infection Prophylaxis 0.8%
Ischaemic Heart Disease Prophylaxis 0.8%
Candidiasis 0.8%
Vomiting 14.6%
Myocardial Infarction 13.9%
Pseudomembranous Colitis 8.8%
Weight Decreased 8.8%
Intracranial Aneurysm 6.6%
Death 5.1%
Upper Gastrointestinal Haemorrhage 5.1%
Meningeal Disorder 4.4%
Liver Function Test Abnormal 3.6%
Ventricular Septal Defect 3.6%
Osteomyelitis 2.9%
Osteonecrosis 2.9%
Sinus Bradycardia 2.9%
Urine Amphetamine Positive 2.9%
Weight Increased 2.9%
Diffuse Large B-cell Lymphoma 2.2%
Hepatitis Acute 2.2%
Hydrocephalus 2.2%
Hypertension 2.2%
Pulmonary Embolism 2.2%
Interacting
Drug Exposure During Pregnancy 57.1%
Drug Use For Unknown Indication 42.9%
Drug Level Increased 50.0%
Placental Insufficiency 50.0%